PALLA, ROBERTA
PALLA, ROBERTA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency
2022 C. Pier Giorgio, Z. Ezio, P. Samantha, P. Federico, L. Banov, C. Biasioli, P. Di Gregorio, A. Ferretti, A. Claudio Molinari, L. Dora Notarangelo, R. Palla, F. Payvandi, M. Pizzuti, B. Pollio, G. Sottilotta, S. Maria Siboni
Hemostatic alterations in COVID-19
2021 F. Peyvandi, A. Artoni, C. Novembrino, S. Aliberti, M. Panigada, M. Boscarino, R. Gualtierotti, F. Rossi, R. Palla, I. Martinelli, G. Grasselli, F. Blasi, A. Tripodi
No changes of parameters nor coagulation activation in healthy subjects vaccinated for {SARS}-Cov-2
2021 F. Payvandi, E. Scalambrino, M. Clerici, A. Lecchi, N. Revelli, R. Palla, R. Gualtierotti, D. Prati, A. Tripodi
Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A
2021 S. Hassan, R. Palla, C. Valsecchi, I. Garagiola, A. El-Beshlawy, M. Elalfy, V. Ramanan, P. Eshghi, M. Karimi, S.C. Gouw, P.M. Mannucci, F.R. Rosendaal, F. Peyvandi
Lombardy Network for the Study and Treatment of Patients Undergoing Apheresis
2020 I. Mancini, P. Agosti, M. Boscarino, B. Ferrari, A. Artoni, R. Palla, L. Barcella, A. Falanga, F. Peyvandi
An international registry of patients with plasminogen deficiency (HISTORY)
2020 A.D. Shapiro, M. Menegatti, R. Palla, M. Boscarino, C. Roberson, P. Lanzi, J. Bowen, C. Nakar, I.A. Janson, F. Peyvandi
Lombardy network for the study and treatment of patients undergoing apheresis
2020 I. Mancini, P. Agosti, M. Boscarino, B. Ferrari, A. Artoni, R. Palla, L. Barcella, A. Falanga, F. Peyvandi
IgG subclasses as biomarkers for persistence of factor VIII inhibitors in previously untreated patients with severe haemophilia A
2020 F. Peyvandi, S. Miri, P. Bucciarelli, C. Valsecchi, L. Schiavone, M. Boscarino, R. Palla, P.M. Mannucci, F.R. Rosendaal
Further comments on "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis"
2019 A. Messori, F. Peyvandi, S. Trippoli, R. Palla, F.R. Rosendaal, P.M. Mannucci
Role of the factor VIII-binding capacity of endogenous von Willebrand factor on the development of factor VIII inhibitors in patients with severe hemophilia A
2019 Y. Repessé, C. Costa, R. Palla, E. Farrokhi Moshai, A. Borel-Derlon, R. D'Oiron, C. Rothschild, A. El-Beshlawy, M. Elalfy, V. Ramanan, P. Eshghi, J. Oldenburg, A. Pavlova, F.R. Rosendaal, F. Peyvandi, S.V. Kaveri, S. Lacroix-Desmazes
Clinical and Laboratory Features of Patients with Acquired Thrombotic Thrombocytopenic Purpura: Fourteen Years of the Milan TTP Registry
2019 I. Mancini, S. Pontiggia, R. Palla, A. Artoni, C. Valsecchi, B. Ferrari, D. Mikovic, F. Payvandi
Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis
2018 F. Peyvandi, A. Cannavò, I. Garagiola, R. Palla, P.M. Mannucci, F.R. Rosendaal, A. El-Beshlawy, M. Elalfy, V. Ramanan, P. Eshghi, S. Hanagavadi, R. Varadarajan, M. Karimi, M.V. Manglani, C. Ross, G. Young, T. Seth, S. Apte, D.M. Nayak, E. Santagostino, M. Elisa Mancuso, A.C. Sandoval Gonzalez, J.N. Mahlangu, S. Bonanad Boix, M. Cerqueira, N.P. Ewing, C. Male, T. Owaidah, V. Soto Arellano, N.L. Kobrinsky, S. Majumdar, R. Perez Garrido, A. Sachdeva, M. Simpson, M. Thomas, E. Zanon, B. Antmen, K. Kavakl, M.J. Manco-Johnson, M. Martinez, E. Marzouka, M.G. Mazzucconi, D. Neme, A. Palomo Bravo, R. Paredes Aguilera, A. Prezotti, K. Schmitt, B.M. Wicklund, B. Zulfikar
High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis
2018 A. Messori, F. Peyvandi, S. Trippoli, R. Palla, F.R. Rosendaal, P.M. Mannucci
Choices of factor VIII products in previously untreated patients with haemophilia A: A global survey
2018 F. Payvandi, R. Palla, C. Franchi, A. Nobili, F.R. Rosendaal, P.M. Mannucci
Risk factors for inhibitor development in severe hemophilia A
2018 I. Garagiola, R. Palla, F. Peyvandi
Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A
2017 A. Cannavò, C. Valsecchi, I. Garagiola, R. Palla, P.M. Mannucci, F.R. Rosendaal, F. Peyvandi
Minimal factor XIII activity level to prevent major spontaneous bleeds : reply
2017 M. Menegatti, R. Palla, P. Bucciarelli, F. Peyvandi
Detection of Factor XIII deficiency: data from multicentre exercises amongst UK NEQAS and PRO-RBDD project laboratories
2017 I. Jennings, S. Kitchen, M. Menegatti, R. Palla, I. Walker, M. Makris, F. Peyvandi
SIPPET: methodology, analysis and generalizability
2017 F. Peyvandi, P.M. Mannucci, R. Palla, F.R. Rosendaal
Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A : A SIPPET analysis
2017 F.R. Rosendaal, R. Palla, I. Garagiola, P.M. Mannucci, F. Peyvandi